Brief: Sino Biopharmaceutical Says TQB3205 Pan-Kras Inhibitor Receives NMPA Clinical Trial Approval
11/03/2026 17:05
March 11 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: TQB3205 PAN-KRAS INHIBITOR RECEIVES NMPA CLINICAL TRIAL APPROVAL FOR ADVANCED MALIGNANT TUMORS Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up